Deferasirox-Fe3-chelate-DataSheet-生命科學(xué)試劑-MedChemExpress

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEDeferasirox Fe3+ chelateCat. No.: HY-16564CAS No.: 554435-83-5分式: CHFeNO分量: 426.18作靶點(diǎn): Others作通路: Others儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DMSO : 50 mg/mL (117.32 mM; Need ultrasonic)

2、Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 2.3464 mL 11.7321 mL 23.4643 mL5 mM 0.4693 mL 2.3464 mL 4.6929 mL10 mM 0.2346 mL 1.1732 mL 2.3464 mL請根據(jù)產(chǎn)品在不同溶劑中的溶解度，選擇合適的溶劑配制儲(chǔ)備液，并請注意儲(chǔ)備液的保存式和期限。體內(nèi)實(shí)驗(yàn) 請根據(jù)您的實(shí)驗(yàn)動(dòng)物和給藥式選擇適當(dāng)?shù)娜芙獍福渲魄罢埾扰渲瞥吻宓膬?chǔ)備液，再依次添加助溶劑(為保證實(shí)驗(yàn)結(jié)果的可靠性，體內(nèi)實(shí)驗(yàn)的作液，建議您現(xiàn)現(xiàn)配，當(dāng)天使；澄清的儲(chǔ)備液可以根據(jù)儲(chǔ)存條件，適當(dāng)保存；以下溶劑

3、前的百分 指該溶劑在您配制終溶液中的體積占)：1. 請依序添加每種溶劑： 10% DMSO 40% PEG300 5% Tween-80 45% salineSolubility: 2.5 mg/mL (5.87 mM); Clear solution2. 請依序添加每種溶劑： 10% DMSO 90% (20% SBE-CD in saline)Solubility: 2.5 mg/mL (5.87 mM); Clear solutionBIOLOGICAL ACTIVITY1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemE物活性 Defera

4、sirox Fe3+ chelate服的鐵螯合劑。體外研究 Deferasirox is the first oral medication approved in the USA for this purpose. The half-life of deferasirox isbetween 8 and 16 hours allowing once a day dosing. Two molecules of deferasirox are capable of binding to1 atom of iron which are subsequently eliminated by fec

5、al excretion. Its low molecular weight and highlipophilicity allows the drug to be taken orally unlike desferoxamine which has to be administered by IV route(intravenous infusion). Together with deferiprone, deferasirox seems to be capable of removing iron fromcells (cardiac myocytes and hepatocytes

6、) as well as removing iron from the blood.REFERENCES1. Yang LP, Keam SJ, Keating GM. Deferasirox : a review of its use in the management of transfusional chronic iron overload. Drugs.2007;67(15):2211-30.2. Kontoghiorghes GJ. Introduction of higher doses of deferasirox: better efficacy but not effect

7、ive iron removal from the heart andincreased risks of serious toxicities. Expert Opin Drug Saf. 2010 Jul;9(4):633-41.3. Galanello R, Campus S, Origa R. Deferasirox: pharmacokinetics and clinical experience. Expert Opin Drug Metab Toxicol. 2012Jan;8(1):123-34.4. Donnelly JP, Lahav M. Deferasirox as a

8、djunctive therapy for mucormycosis. J Antimicrob Chemother. 2012 Mar;67(3):519-20.5. Lui GY, Obeidy P, Ford SJ et al. The Iron Chelator, Deferasirox, as a Novel Strategy for Cancer Treatment: Oral Activity Against HumanLung Tumor Xenografts and Molecular Mechanism of Action. Mol Pharmacol. 2012 Oct 16. Epub ahead of printMcePdfHeightCaution: Product has not been fully validated for medical application